Enanta Pharmaceuticals (ENTA) Competitors

$13.45 +0.04 (+0.30%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$13.58 +0.13 (+0.97%)

As of 04:47 AM Eastern

ENTA vs. NTLA, NUVB, VCEL, RXRX, and NRIX

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to Intellia Therapeutics?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 21 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 25 mentions for Intellia Therapeutics and 4 mentions for Enanta Pharmaceuticals. Intellia Therapeutics' average media sentiment score of 0.32 beat Enanta Pharmaceuticals' score of -1.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Negative
Intellia Therapeutics	Neutral

Enanta Pharmaceuticals has higher earnings, but lower revenue than Intellia Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.99	-$81.89M	-$2.59	N/A
Intellia Therapeutics	$67.67M	26.20	-$412.69M	-$3.54	N/A

Enanta Pharmaceuticals has a net margin of -89.56% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Enanta Pharmaceuticals presently has a consensus price target of $20.29, suggesting a potential upside of 50.82%. Intellia Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 59.57%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Enanta Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

Summary

Intellia Therapeutics beats Enanta Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Nuvation Bio and Nuvation Bio both had 4 articles in the media. Nuvation Bio's average media sentiment score of 0.40 beat Enanta Pharmaceuticals' score of -1.00 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvation Bio	Neutral
Enanta Pharmaceuticals	Negative

Enanta Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	23.33	-$204.63M	-$0.43	N/A
Enanta Pharmaceuticals	$65.32M	5.99	-$81.89M	-$2.59	N/A

Enanta Pharmaceuticals has a net margin of -89.56% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Nuvation Bio currently has a consensus price target of $12.50, indicating a potential upside of 196.56%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 50.82%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Nuvation Bio has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Summary

Nuvation Bio beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Vericel?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, Vericel had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Enanta Pharmaceuticals. Vericel's average media sentiment score of 0.55 beat Enanta Pharmaceuticals' score of -1.00 indicating that Vericel is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Negative
Vericel	Positive

Enanta Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Vericel has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus price target of $20.29, indicating a potential upside of 50.82%. Vericel has a consensus price target of $55.40, indicating a potential upside of 58.88%. Given Vericel's higher probable upside, analysts plainly believe Vericel is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vericel has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.99	-$81.89M	-$2.59	N/A
Vericel	$292.09M	6.10	$16.52M	$0.42	83.02

Vericel has a net margin of 7.35% compared to Enanta Pharmaceuticals' net margin of -89.56%. Vericel's return on equity of 6.41% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Vericel	7.35%	6.41%	4.61%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Vericel beats Enanta Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Recursion Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Recursion Pharmaceuticals presently has a consensus price target of $8.10, suggesting a potential upside of 180.28%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 50.82%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has lower revenue, but higher earnings than Recursion Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	20.51	-$644.76M	-$1.20	N/A
Enanta Pharmaceuticals	$65.32M	5.99	-$81.89M	-$2.59	N/A

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 4 mentions for Enanta Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.66 beat Enanta Pharmaceuticals' score of -1.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Recursion Pharmaceuticals	Positive
Enanta Pharmaceuticals	Negative

Summary

Recursion Pharmaceuticals beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Nurix Therapeutics?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Enanta Pharmaceuticals has higher earnings, but lower revenue than Nurix Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.99	-$81.89M	-$2.59	N/A
Nurix Therapeutics	$83.98M	19.10	-$264.46M	-$3.16	N/A

In the previous week, Nurix Therapeutics had 6 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 10 mentions for Nurix Therapeutics and 4 mentions for Enanta Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 0.58 beat Enanta Pharmaceuticals' score of -1.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Negative
Nurix Therapeutics	Positive

Enanta Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus target price of $20.29, suggesting a potential upside of 50.82%. Nurix Therapeutics has a consensus target price of $30.46, suggesting a potential upside of 96.40%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Nurix Therapeutics' net margin of -411.37%. Enanta Pharmaceuticals' return on equity of -64.04% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Summary

Nurix Therapeutics beats Enanta Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$389.94M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.32%
P/E Ratio	-5.19	17.22	20.64	25.23
Price / Sales	5.99	286.32	554.85	79.36
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	4.44	3.93	9.66	6.63
Net Income	-$81.89M	$74.99M	$3.56B	$335.59M
7 Day Performance	-7.43%	-4.47%	-1.65%	-1.20%
1 Month Performance	-4.00%	-7.93%	-2.60%	-1.16%
1 Year Performance	125.67%	29.34%	30.07%	28.10%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.6708 of 5 stars	$13.45 +0.3%	$20.29 +50.8%	+133.9%	$389.94M	$65.32M	N/A	160
NTLA Intellia Therapeutics	2.839 of 5 stars	$13.99 -3.0%	$20.36 +45.6%	+49.3%	$1.69B	$67.67M	N/A	600	Analyst Downgrade
NUVB Nuvation Bio	2.9195 of 5 stars	$4.85 +1.8%	$12.50 +158.0%	+86.9%	$1.68B	$143.05M	N/A	60
VCEL Vericel	3.8514 of 5 stars	$32.94 +0.1%	$55.40 +68.2%	-17.9%	$1.68B	$276.26M	78.43	300	Analyst Downgrade
RXRX Recursion Pharmaceuticals	3.1234 of 5 stars	$3.15 -3.4%	$9.20 +192.1%	-36.6%	$1.66B	$65.74M	N/A	400	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. NTLA, NUVB, VCEL, RXRX, and NRIX

How does Enanta Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Enanta Pharmaceuticals compare to Nuvation Bio?

Summary

How does Enanta Pharmaceuticals compare to Vericel?

Summary

How does Enanta Pharmaceuticals compare to Recursion Pharmaceuticals?

Summary

How does Enanta Pharmaceuticals compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. NTLA, NUVB, VCEL, RXRX, and NRIX

How does Enanta Pharmaceuticals compare to Intellia Therapeutics?

Do institutionals & insiders hold more shares of ENTA or NTLA?

Does the media prefer ENTA or NTLA?

Which has better valuation and earnings, ENTA or NTLA?

Is ENTA or NTLA more profitable?

Do analysts prefer ENTA or NTLA?

Which has more volatility and risk, ENTA or NTLA?

Summary

How does Enanta Pharmaceuticals compare to Nuvation Bio?

Do insiders & institutionals hold more shares of NUVB or ENTA?

Does the media refer more to NUVB or ENTA?

Which has stronger valuation and earnings, NUVB or ENTA?

Is NUVB or ENTA more profitable?

Do analysts prefer NUVB or ENTA?

Which has more volatility and risk, NUVB or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Vericel?

Does the media prefer ENTA or VCEL?

Which has more volatility and risk, ENTA or VCEL?

Do analysts recommend ENTA or VCEL?

Which has higher valuation & earnings, ENTA or VCEL?

Is ENTA or VCEL more profitable?

Do insiders and institutionals believe in ENTA or VCEL?

Summary

How does Enanta Pharmaceuticals compare to Recursion Pharmaceuticals?

Do insiders and institutionals hold more shares of RXRX or ENTA?

Is RXRX or ENTA more profitable?

Which has more risk and volatility, RXRX or ENTA?

Do analysts prefer RXRX or ENTA?

Which has preferable earnings and valuation, RXRX or ENTA?

Does the media favor RXRX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Nurix Therapeutics?

Which has preferable earnings and valuation, ENTA or NRIX?

Does the media prefer ENTA or NRIX?

Which has more risk & volatility, ENTA or NRIX?

Do analysts prefer ENTA or NRIX?

Do insiders & institutionals hold more shares of ENTA or NRIX?

Is ENTA or NRIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools